SCHEMBL6880352

SCHEMBL6880352

CC(C)(C)OC(=O)N(c1ccc(Cl)cc1)[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MT-CO2 P00403 1/20 0.46
NR1D1 P20393 2/20 0.40
NR1H3 Q13133 1/20 0.40
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
STS P08842 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C19 P33261 1/20 0.35
PPARA Q07869 1/20 0.35
GAA P10253 1/20 0.35
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL248463 0.84 ALDH1A1 (0.41) MEN1KMT2ACYP3A4CYP2C19ALDH1A1
SCHEMBL6878251 0.82 RAB9A (0.39) MT-CO2MEN1KMT2AMAPTGAA
SCHEMBL17336893 0.79 NOTUM (0.36) MT-CO2NR1H3CYP3A4POLBLMNA
SCHEMBL979761 0.78 MAPT (0.49) MEN1KMT2ACYP1A2MAPTCYP2C19
SCHEMBL979206 0.77 GPR119 (0.42)
SCHEMBL2133261 0.77 GABRA5 (0.39) MT-CO2
SCHEMBL7112682 0.77 KCNH2 (0.41) MEN1KMT2AMAPTALDH1A1
SCHEMBL20163048 0.76 USP30 (0.42)
SCHEMBL978403 0.76 GPR119 (0.43)
SCHEMBL1007329 0.76 MT-CO2 (0.51) MT-CO2MEN1KMT2ASTSCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed